Is TB-500 legal in Australia?

TB-500 is not ARTG-registered. Australian therapeutic-goods and import restrictions apply; an online research listing is not a medicine approval.

What safety and evidence questions need assessment?

Relevant questions include the quality of human studies, possible interactions, medical conditions that affect risk and gaps in long-term safety information.

Unapproved peptide fragment

TB-500 in Australia: Legal Status & Evidence

Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.

Overview

TB-500 is associated with thymosin beta-4 research. Findings about the full protein, fragments and research products are not interchangeable evidence of human safety or clinical benefit.

Indications reviewed at consultation

Medical history, allergies and previous treatment
Current medicines and potential interactions
Pregnancy, breastfeeding and relevant health conditions

Administration

TB-500 research products cannot be treated as equivalent to thymosin beta-4 studied in the scientific literature.

Cautions

Not for use in pregnancy, breastfeeding, or active malignancy. Long-term human safety data is limited. WADA-prohibited substance — do not use if you compete in WADA-tested sport.

Frequently asked questions

Is TB-500 legal in Australia?: TB-500 is not ARTG-registered. Australian therapeutic-goods and import restrictions apply; an online research listing is not a medicine approval.
What safety and evidence questions need assessment?: Relevant questions include the quality of human studies, possible interactions, medical conditions that affect risk and gaps in long-term safety information.

Educational content only. Whether any treatment is appropriate, and whether it can lawfully be supplied in Australia, is a decision for a registered doctor and the TGA.

General information only, not medical advice. The treating doctor decides whether any treatment is appropriate.

Important information

Official sources — regulatory context

These sources explain medicine regulation, access and health advertising requirements; they do not endorse this site. An educational disclaimer does not establish compliance or replace advice from a registered clinician.

Related peptides

Unapproved peptide

BPC-157

Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.

Regulatory status

CJC-1295 + Ipamorelin

Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.

Regulatory status

Ipamorelin

Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.

Regulatory status

AOD-9604

Evidence limitations and individual safety require clinical assessment. Registration and lawful supply must be checked; this information is not a treatment recommendation.

Australian consultation information by city

Questions about your options?

Learn how a telehealth consultation with an AHPRA-registered Australian doctor works. Whether any treatment is appropriate is a decision your doctor makes based on your individual clinical needs.

How Australian access pathways work